Artificial intelligence is rapidly reshaping the pharmaceutical industry—and nowhere is that more evident than in small-molecule drug discovery. In this episode, we sit down with Tom Shani, CEO and co-founder of ProPhet, an AI-driven biotech company focused on discovering drugs for hard-to-target proteins.Tom explains how machine learning models, transformers, and AI-driven molecular representations are overcoming the biggest limitations of traditional drug discovery: slow timelines, high failure rates, missing data, and b...
Artificial intelligence is rapidly reshaping the pharmaceutical industry—and nowhere is that more evident than in small-molecule drug discovery. In this episode, we sit down with Tom Shani, CEO and co-founder of ProPhet, an AI-driven biotech company focused on discovering drugs for hard-to-target proteins.
Tom explains how machine learning models, transformers, and AI-driven molecular representations are overcoming the biggest limitations of traditional drug discovery: slow timelines, high failure rates, missing data, and billion-dollar R&D costs. Rather than relying solely on physics-based simulations and trial-and-error lab work, AI systems learn patterns directly from noisy biological data—making them uniquely suited for real-world biology.
The conversation explores how AI can compress drug discovery timelines from decades to years, reduce failed trials, and dramatically lower costs by improving early-stage target and molecule selection. Tom also breaks down why small molecules remain the backbone of modern medicine, how AI enables scalable exploration of vast chemical space, and why trust, regulation, and validation remain the biggest hurdles to adoption.
This episode is essential listening for anyone working in pharma R&D, biotech, AI-driven drug discovery, computational biology, or life sciences innovation.
Topics Covered- AI-powered small-molecule drug discovery
- Machine learning vs traditional pharmaceutical R&D
- Hard-to-drug proteins and undruggable targets
- Transformers, AlphaFold, and molecular representations
- Reducing drug discovery timelines and costs
- AI robustness to missing and noisy biological data
- Off-target effects, toxicity, and safety prediction
- The future of AI in pharma and biotech startups
About the Podcast
AI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.
This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.
AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget.
As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses.
This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more.
Dr. Andree Bates LinkedIn | Facebook | Twitter
